Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Mar;53(5):640-641.
doi: 10.1111/apt.16212.

Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game

Xavier Roblin  1 , Stéphane Paul  2 , Stéphane Nancey  3
Affiliations
Editorial

Editorial: anti-TNF agents against vedolizumab as a second-line treatment? Not surprising tie game

Xavier Roblin et al. Aliment Pharmacol Ther. 2021 Mar.
No abstract available

PubMed Disclaimer

Comment in

Comment on

References

REFERENCES

    1. Rundquist S, Sachs MC, Erikson C, et al. Drug survival of anti-TNF agents compared with vedolizumab as a second-line biological treatment in inflammatory bowel disease: results from nationwide Swedish registers. Alimentary Pharmacol Ther. 2021;53:471-483.
    1. Mitrev N, Vande Casteele N, Seow CH, et al. Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases. Aliment Pharmacol Ther. 2017;46:1037-1053.
    1. Lamb CA, Kennedy NA, Raine T, et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut. 2019;68:s1-s106.
    1. Vande Casteele N, Herfarth H, Katz J, et al. American Gastroenterological Association Institute Technical Review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology. 2017;153:835-857.
    1. Yanai H, Lichtenstein L, Assa A, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol. 2015;13:522-530.

Substances

LinkOut - more resources